Estrogen and Raloxifene Activities on Amyloid-β-Induced Inflammatory Reaction
Authors:
- Margie BryantaMBMargie Bryanta
- Linda ClarkaLCLinda Clarka
- Amanda GarcesaAGAmanda Garcesa
- Johannes RhodinaJRJohannes Rhodina
- 1 January 2001
- journal article
- research article
- Published by Elsevier in Microvascular Research
- Vol. 61 (1) , 28-39
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Estrogen for Alzheimer’s disease in womenNeurology, 2000
- Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivatorsProceedings of the National Academy of Sciences, 1999
- Adverse events reported by postmenopausal women in controlled trials with raloxifeneObstetrics & Gynecology, 1999
- Estradiol Protects against Ischemic InjuryJournal of Cerebral Blood Flow & Metabolism, 1998
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Raloxifene Inhibits Aortic Accumulation of Cholesterol in Ovariectomized, Cholesterol-Fed RabbitsCirculation, 1997
- A pharmacological review of raloxifeneJournal of Bone and Mineral Metabolism, 1996
- Modulation of Endothelium-Dependent Flow-Mediated Dilatation of the Brachial Artery by Sex and Menstrual CycleCirculation, 1995
- Raloxifene is a Tissue‐Selective Agonist/Antagonist That Functions through the Estrogen ReceptorAnnals of the New York Academy of Sciences, 1995
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992